Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exenatide long-acting - AstraZeneca

Next Previous
X
Search
Drug Profile

Exenatide long-acting - AstraZeneca

Alternative Names: Bydureon; BYDUREON BCise; Bydureon Pen; Byetta LAR; Exenatide extended-release for injectable suspension; Exenatide LAR; Exenatide once-weekly suspension; Ready to Use Exenatide Once Weekly

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amylin Pharmaceuticals
  • Developer AstraZeneca; Eli Lilly and Company; University Medical Center Hamburg-Eppendorf
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II Obesity

Most Recent Events

  • 29 Jul 2022 Launched for Type 2 diabetes mellitus (In adolescents, In children) in Sweden, Switzerland, Slovakia, Portugal, Norway, Netherlands, Lithuania, Latvia, Hungary, Ireland, Germany, Finland, Denmark, Czech Republic, Austria (SC) before July 2022
  • 29 Jul 2022 Preregistration for Type 2 diabetes mellitus (In adolescents, In children) in European Union before July 2022 (SC)
  • 29 Jul 2022 Registered for Type 2 diabetes mellitus (In adolescents, In children) in European Union (SC) before July 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top